<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02729623</url>
  </required_header>
  <id_info>
    <org_study_id>cannaHALER-1A</org_study_id>
    <nct_id>NCT02729623</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics, Safety, and Ease of Use of a Portable Metered-Dose Cannabis Inhaler</brief_title>
  <official_title>The Pharmacokinetics, Safety, and Ease of Use of a Portable Metered-Dose Cannabis Inhaler: A Phase 1a Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite Systems</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kite Systems</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Growing evidence supports the use of inhaled cannabis for neuropathic pain; the lack of&#xD;
      standard inhaled dosing holds a major obstacle in cannabis becoming a pharmacological&#xD;
      treatment for neuropathic pain. The objective of this study is to explore the&#xD;
      pharmacokinetics, safety, tolerability, and ease of use of a portable metered-dose inhaler,&#xD;
      (i.e. CannaHALER) for cannabis in a cohort of 12 healthy volunteers. In a single escalating&#xD;
      dose methodology, open-label study, patients will inhale a single 10 ± 0.1 mg / 15 ± 0.1 mg /&#xD;
      20 ± 0.1 mg / 25 ± 0.1 mg dose of cannabis using the Kite Systems cannaHALER cannabis Inhaler&#xD;
      device. Blood samples will be taken at baseline and up to 30 minutes. Adverse events will be&#xD;
      monitored following the inhalation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Δ9-tetrahydrocannabinol levels (THC)</measure>
    <time_frame>30 Minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse event monitoring</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Δ9 Carboxy-THC levels</measure>
    <time_frame>30 Minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short Blessed cognitive Test</measure>
    <time_frame>30 Minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>120 Minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse rate</measure>
    <time_frame>120 Minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation</measure>
    <time_frame>120 Minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single CannaHALER dose 10 ± 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 10 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single CannaHALER dose 15 ± 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 15 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single CannaHALER dose 20 ± 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 20 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single CannaHALER dose 25 ± 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose 25 ± 0.1 mg of cannabis using the Kite Systems CannaHALER cannabis Inhaler device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kite Systems cannaHALER cannabis Inhaler.</intervention_name>
    <arm_group_label>Single CannaHALER dose 10 ± 0.1 mg</arm_group_label>
    <arm_group_label>Single CannaHALER dose 15 ± 0.1 mg</arm_group_label>
    <arm_group_label>Single CannaHALER dose 20 ± 0.1 mg</arm_group_label>
    <arm_group_label>Single CannaHALER dose 25 ± 0.1 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  aged 30-70 years;&#xD;
&#xD;
          -  healthy&#xD;
&#xD;
          -  if applicable, negative pregnancy test (β human chorionic gonadotropin pregnancy&#xD;
             test).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  significant cardiac or pulmonary disease,&#xD;
&#xD;
          -  history of a psychotic or anxiety disorder,&#xD;
&#xD;
          -  pregnancy, pregnancy attempt or breastfeeding,&#xD;
&#xD;
          -  presence of a neuropathic or non-neuropathic pain,&#xD;
&#xD;
          -  low blood pressure, below 90 mm Hg (systolic)&#xD;
&#xD;
          -  Diabetes is diagnosed,&#xD;
&#xD;
          -  first degree family history of psychotic or anxiety disorder,&#xD;
&#xD;
          -  history of drug addiction,&#xD;
&#xD;
          -  history of drug misuse,&#xD;
&#xD;
          -  using the following drugs: Rifampicin, Rifabutin, Carbamazepine, Phenobarbital,&#xD;
             Primidone,&#xD;
&#xD;
          -  using the following plants: Hypericum perforatum, troglitazone,&#xD;
&#xD;
          -  Alcohol consumption up to 12 hours before the study,&#xD;
&#xD;
          -  abnormal parameters such as Heart Rate above 100 BPM, Blood pressure, below 90 mm Hg&#xD;
             (systolic), Saturation below 91 percent,&#xD;
&#xD;
          -  Cannabis use up to 12 hours before the study,&#xD;
&#xD;
          -  health condition which could affect or alter the experiment results,&#xD;
&#xD;
          -  Volunteer has a legal guardian.&#xD;
&#xD;
          -  Chronic use of drugs,&#xD;
&#xD;
          -  age less than 30 or more than 70,&#xD;
&#xD;
          -  a health condition that could affect the outcome of the trial or constitutes a risk&#xD;
             factor for participation in the trial.&#xD;
&#xD;
          -  The experiment will not include special populations such as pregnant women, children&#xD;
             and without judgement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ofir Ben-Ishay, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Health Care Campus</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>March 27, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <last_update_submitted>July 22, 2016</last_update_submitted>
  <last_update_submitted_qc>July 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

